Relay Therapeutics, Inc.
RLAY
$12.78
-$0.44-3.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -60.93% | -- | -- | -- | -23.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.93% | -- | -- | -- | -23.26% |
| Cost of Revenue | -4.40% | -12.56% | -11.39% | -33.18% | -10.43% |
| Gross Profit | -2.17% | 23.42% | 11.39% | 33.91% | 8.66% |
| SG&A Expenses | -41.15% | -33.86% | -36.70% | -31.71% | -5.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.84% | -17.71% | -16.58% | -32.91% | -9.45% |
| Operating Income | 7.40% | 25.95% | 16.58% | 33.52% | 7.95% |
| Income Before Tax | 4.90% | 27.78% | 15.84% | 23.68% | 5.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.90% | 27.78% | 15.84% | 23.68% | 5.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.90% | 27.78% | 15.84% | 23.68% | 5.31% |
| EBIT | 7.40% | 25.95% | 16.58% | 33.52% | 7.95% |
| EBITDA | 6.66% | 25.48% | 16.17% | 33.60% | 7.86% |
| EPS Basic | 10.52% | 30.32% | 31.55% | 40.82% | 26.78% |
| Normalized Basic EPS | 10.51% | 27.40% | 31.55% | 49.04% | 28.40% |
| EPS Diluted | 10.52% | 30.32% | 31.55% | 40.82% | 26.78% |
| Normalized Diluted EPS | 10.51% | 27.40% | 31.55% | 49.04% | 28.40% |
| Average Basic Shares Outstanding | 6.27% | 3.63% | 22.93% | 28.94% | 29.34% |
| Average Diluted Shares Outstanding | 6.27% | 3.63% | 22.93% | 28.94% | 29.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |